Viruses are constantly mutating,
taking on new and daunting characteristics which make it more and more
difficult for medical science to thwart them, especially when the only tools
available are based on centuries old technology. The growing concern over the
Zika virus, for instance, with nearly 4,500 confirmed cases in Brazil
(http://dtn.fm/80KgF) and cases cropping up here in the U.S.
(http://dtn.fm/iJe94), has lit a fire under the biotech sector, but a hoped-for
vaccine could only be partially effective at fighting the spread. President
Barack Obama recently asked Congress for $1.8 billion in emergency funding that
would, in part, help expedite the development of a Zika vaccine. While Inovio
Pharmaceuticals (NASDAQ: INO) has shown positive signs (http://dtn.fm/dngJ3)
with its nascent vaccine, human trials won’t see the light of day until the end
of this year.
The real kicker, though, is that,
even if a vaccine is developed, it may be only marginally effective at stopping
something like Zika, which is now even more readily asserted to be sexually
transmissible (http://dtn.fm/7KlhH), directly linked to microcephaly
(http://dtn.fm/0zI3B) in the newborn infants of infected women and even the
paralyzing Guillain-Barre syndrome (http://dtn.fm/IP1kw). As is the case with
seasonal influenza (flu) vaccines, overall efficacy is the real bottom line,
and the CDC’s own numbers (http://dtn.fm/Czzi9) indicate that for the 2014 to
2015 season, adjusted overall efficacy was a mere 23 percent.
What we really need here is something
new – a new and more agile weapon system based on truly 21st century
technology. Development-stage NanoViricides (NYSE MKT: NNVC), with its
nanotechnology-based biomimetic anti-viral medicines called nanoviricides®
looks to be the answer to a question that, sadly, many in the medical community
aren’t even asking yet. This technology could rightly be considered a
“penicillin” for viruses due to the breadth of application, speed with which
new indications can be developed, and show-stopping efficacy potential, and the
company’s proprietary nanoviricides are also able to be administered orally (as
well as through injection) in certain cases. Oral FluCide™, for instance, which
NNVC proudly proclaims to be the first ever oral nanomedicine, has been shown
to be substantially superior (http://dtn.fm/Ef7RD) to Roche’s (OTC: RHHBY)
TamiFlu® (Oseltamivir) in animal models (Totally Lethal Infection Study) and
exhibited broad-spectrum efficacy (Influenza A H1N1 and H3N2). Oral Flucide has
also shown clear indication that a full clinical recovery is possible, even in
high path, severe influenzas.
NanoViricides has received the
IAIR AWARD as Best North American Company for Leadership in the Nanomedicine
Sector from the prestigious IAIR® Group, the Milan-headquartered research
institute and independent publishing house with major shareholders from Europe
and Asia which has over a decade in global economy and sustainability
publishing. This revolutionary company has developed a simple, yet powerful,
antiviral platform technology employing the combination of a nanomicelle
polymer that engulfs the target cell (http://dtn.fm/L2pcG), and mimic receptor
proteins known as ligands, which lure the targeted virus to attack the
nanoviricide. This platform’s key advantage of being able to trick the targeted
virus into thinking the nanoviricide is a normal human cell via the ligands,
which do not substantially change even when a virus mutates to a new form that
may be resistant to other measures, is reinforced ably by NNVC’s proprietary
method for quickly creating the unique ligands which are used. Because of this
sweeping unification of efficacy and developmental capabilities, nanoviricides
are not only suitable for attacking otherwise impossible to defeat viral agents
on a commercial scale, they can also be rapidly developed in the field as a
frontline measure to combat fast-mutating viruses using the company’s ADIF™
(Accurate-Drug-In-Field) technology.
Because the technique for field
developing targeted therapeutics using ADIF involves the same tried and tested
methodology as for any other nanoviricide – deriving the virus-binding ligand
from the binding site of the virus cell surface receptor – the capacity to
create an effective, targeted therapeutic in the midst of an outbreak, with
only a small lab setup, is an advantage moving forward for NNVC that represents
a tremendous value proposition to investors. Additionally, since the ADIF
technology does not require any specific identification of the actual virus or
difficult to obtain understanding of the specific molecular biology of the
pathogen in question, a rapid-deployment nanoviricide, made using nanomicelles
that have been stockpiled beforehand, effectively constitutes a field-ready
smart weapon that is as adaptable as the most daunting viruses in existence,
such as H5N1, SARS, and Ebola.
The combined market size for
injectable and oral FluCide is likely over $30 billion, and because the
company’s antivirals are so completely focused by design on the target virus,
there is virtually no impact to the host, marking another clear advantage of
this technology over antiquated vaccine technology. These nanoviricides can be
created in weeks, instead of the years often required to develop a vaccine, and
the company already has a robust pipeline of six potential blockbusters that
have been tested in over 6,000 animals. FluCide has produced some amazing
results thus far in animal model work, such as a greater than 1,000-fold lung
viral load reduction, compared to less than two-fold in TamiFlu and the control
group, or 100 percent survival rate at 22 plus days seen in the Totally Lethal
Infection Study, compared to a 100 percent death rate after only eight days
with extended TamiFlu treatment (100 percent death rate after five days with control
group).
The combined estimated market size
for the company’s antiviral eye drops designed to fight
conjunctivitis/keratitis, its HerpeCide™ indication for shingles, as well as
ocular and genital herpes (note that HSV-1 has also been linked to Alzheimer’s),
and its DengueCide™ indication to combat Dengue arboviruses (West Nile, Yellow
Fever, Japanese B Encephalitis), are in the neighborhood of $17 billion. The
market size for NNVC’s HivCide™, which could be the first ever broad-spectrum
weapon to stop the spread of HIV/AIDS, is estimated to be around $22 billion.
The company’s DengueCide indication for Dengue fever and Dengue hemorrhagic
fever is of particular note here, as that virus is in the same family as Zika.
The company already has multiple
pre-clinical studies underway at various universities, HerpeCide is on track
for human trials as early as this year, FluCide is slated for human trials
shortly thereafter, and both the FDA and EMA have granted DengueCide orphan
drug status. To understand the full story of NNVC, though, it is important to
look at the company’s visionary management, including its chairman and
president, Anil R. Diwan, PhD, as well as its CEO, Eugene Seymour MD, MPH, and
CSO, Randall W. Barton, PhD.
Dr. Diwan, a prolific inventor and
serial entrepreneur, pioneered polymeric micelle-based nanomedicine
technologies with his invention of them back in 1991, but he is also the
driving force behind keeping the company’s administrative and R&D costs at
extremely low levels – despite the fact that the company has been aggressively
expanding its pipeline each year. This administrative acumen is due in large
part to his considerable wealth of experience, having founded nanomedicine and
cell-targeted drug delivery, as well as small chemical, device technology and
informatics-focused operations such as TheraCour Pharma and AllExcel, prior to
co-founding NNVC. Dr. Diwan is a patent holder, with three more applications
filed internationally resulting in numerous nation-level patents abroad. He has
received numerous NIH small business innovation research grant awards and has
several patent applications in various stages.
Dr. Seymour has a similarly
eminent history of research and work under his belt, having cut his teeth back
in the 1960’s in LA and Beverly Hills during the rise of the HIV/AIDS epidemic
and having been tapped by the U.S. government to create a testing laboratory,
as well as run a large-scale data generation operation examining HIV prevalence
in LA’s Hispanic population. Dr. Seymour founded the company now known as
Stat-Sure because of his foresight about the importance of prevention in lieu
of a cure for HIV, and he went on to run a large non-profit after leaving the
company in the late 1990’s, spearheading testing and training efforts in Asia
and Africa before going on to be a UN Global Program on AIDS consultant who was
deployed in several other countries. A holder of eight patents whose first love
was chemistry and who initially trained to be a clinical investigator, Dr.
Seymour got his master’s degree in the epidemiology of infectious diseases from
UCLA before going on to do internal medicine work, and later becoming a member
of the USC faculty as an Associate Professor. Dr. Seymour is also a Vietnam
vet, having served in the U.S. Army Reserve Medical Corps during the Vietnam
era, attaining the rank of Major.
Last, but certainly not least, is
NNVC chief science officer Dr. Barton. Dr. Barton, former VP of drug discovery
at personalized oncology innovators A&G Pharmaceuticals, has a rich history
of drug discovery and development on both the small molecule and biological
drug candidate ends of the spectrum, spanning multiple focus areas from
virology and immunology to inflammation. Dr. Barton also possesses a great deal
of experience in cardiovascular disease-related discovery and development from
his collective pharmaceutical/biotech industry work, and he was a director for
two decades at the U.S. pharmaceuticals division of German pharma giant
Boehringer Ingelheim, where he helped do the pre-clinical development on the
important HIV inhibitor drug Viramune (Nevirapine). This is a man with over 80
scientific publication to his name who has an abundance of academic and
teaching experience behind him and who was the principal investigator in the
development of five patents. Dr. Barton received his PhD in biochemistry from
the University of Tennessee at Oak Ridge National Laboratory and was a faculty
member at the University of Connecticut Medical School when he was awarded the
NIH’s Career Development Award for his work doing research and education in the
field of immunology.
Needless to say, NNVC has an
esteemed, deep bench of upper management talent that has continued to produce
bottom line results and mounting shareholder value in the form of its candidate
portfolio. The immense potential of the company’s rapidly developing pipeline
and nanoviricide/ADIF platform technologies themselves cannot really be
properly estimated. Investors need to take a closer look here before the rest of
the world realizes what NNVC has its hands on.
Get ahead of the curve, visit
www.nanoviricides.com
About QualityStocks
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and long-term
future. We offer several ways for investors to find, evaluate, and learn more
about investing in these companies.
Sign up for “The QualityStocks
Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment